Screener
Bristol-Myers Squibb BMY Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.2%-0.1pp | 70.5%0.0pp | 71.1%0.0pp | 69.5%-5.4pp | 70.3%-5.1pp | |
| Net margin | 18.9%+8.4pp | 15%+3.8pp | 14.6%+33.3pp | 12.4%+27.7pp | 10.4%+24.5pp | |
| Returns | ||||||
| Return on equity | 46.7%+17.8pp | 38.8%+7.3pp | 40.5%+79.9pp | 33.4%+64.9pp | 28.9%+55.6pp | |
| Return on invested capital | 16.7%+8.4pp | 13%+4.2pp | 12.5%+27.2pp | 10.6%+22.0pp | 8.3%+18.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.5×+0.3× | 1.4×+0.1× | 1.3×0.0× | 1.3×0.0× | 1.2×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.9×-0.9× | 2.2×-0.6× | 2.6×-0.6× | 2.7×-0.3× | 2.8×-0.3× | |
| Net debt / EBITDA | 2.3×-0.6× | 2.7×-0.1× | 2.8×-36.3× | 2.6×-10.1× | 2.8×-10.0× | |
| Valuation | ||||||
| Market capitalization | $133.41B+44.4% | $123.83B-0.2% | $109.81B-4.3% | $91.8B-12.5% | $95.71B+13.7% | |
| Price / earnings | 14.4×-4.2× | 17×-6.2× | 15.6×— | 15.4×— | 19.2×— | |
| Price / sales | 2.7×+0.8× | 2.6×-0.1× | 2.3×-0.1× | 1.9×-0.3× | 2×+0.2× | |
| Price / book | 6×+0.7× | 6.2×-1.0× | 5.9×-1.1× | 4.9×-1.2× | 5.5×+0.5× | |
| EV / EBITDA | 11.1×+1.1× | 12×+0.4× | 11×-138× | 9.8×-34.7× | 10.3×-25.9× | |
| Dividend yield | 3.8%-1.5pp | 4.1%+0.1pp | 4.6%+0.4pp | 5.4%+0.9pp | 5.2%-0.5pp |
FAQ
- Where do Bristol-Myers Squibb's ratios come from?
- Every ratio is computed from Bristol-Myers Squibb's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
